+91 9425150513 (Asia) support@24lifesciences.com
Regional Analysis, Demand Analysis and Competitive Outlook 2025-2032
The global insulin pen market was valued at USD 5.74 billion in 2025 and is estimated at USD 6.85 billion in 2026. The market is projected to reach USD 28.16 billion by 2034, representing a 19.3% CAGR during 2026–2034.
Insulin pens occupy a distinct position between traditional vial-and-syringe administration and pump-based insulin delivery. Their commercial value rests on dose portability, simplified self-administration, standardized cartridge or prefilled formats and the ability to support frequent outpatient dosing without a capital device installation. The addressable base is therefore tied not only to diabetes prevalence, but also to insulin initiation, treatment persistence, patient training and the share of insulin users who transition from vials to pen presentations.
Product innovation is expanding the category beyond mechanical dose delivery. Novo Nordisk’s NovoPen 6 and NovoPen Echo Plus automatically record the time, date and units of injected doses and can transfer injection histories to compatible applications. At the formulation-device interface, once-weekly insulin is creating a new pen-use case: Awiqli is administered once weekly and has been authorized in multiple markets, changing the relationship between injection frequency, device convenience and adherence.
Access remains a decisive commercial variable. In the United States, Medicare continues to cap beneficiary cost sharing at USD 35 for a month’s supply of each covered insulin product, while the FDA’s February 2025 approval of Merilog introduced the first rapid-acting insulin biosimilar and included a 3 mL prefilled-pen presentation. These changes can widen insulin access while increasing competition among branded, biosimilar and device-linked treatment options.
Source: International Diabetes Federation; U.S. FDA; Novo Nordisk smart pens; CMS.
The study covers insulin pen delivery systems used for subcutaneous insulin administration, with analysis by pen type, diabetes-management application, end user and geography.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Type | Reusable Insulin Pens; Disposable Insulin Pens |
| By Application | Type 1 Diabetes Management; Type 2 Diabetes Management; Gestational Diabetes Care; Other Specialized Applications |
| By End User | Hospitals and Clinics; Homecare Settings; Ambulatory Surgical Centers |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; France; United Kingdom; Italy; China; Japan; South Korea; India; Brazil; Saudi Arabia; United Arab Emirates and other major markets |
| Key Market Players | Novo Nordisk A/S; Sanofi S.A.; Eli Lilly and Company; Ypsomed Holding AG; Owen Mumford Ltd.; Becton, Dickinson and Company |
The market includes reusable insulin pen devices that accept replaceable insulin cartridges and disposable prefilled insulin pens intended for single-patient use. It covers mechanical and connected pen platforms where the core commercial purpose is insulin delivery.
Standalone insulin vials used without pen devices, insulin pumps, continuous glucose monitoring systems, conventional syringes and non-insulin pen injectors fall outside the core scope. Digital applications are discussed only when they are integrated with, or materially affect adoption of, insulin pen systems.
The International Diabetes Federation estimates 589 million adults aged 20–79 are living with diabetes worldwide, with the figure projected to reach 853 million by 2050. Insulin use is concentrated within only part of this population, but the scale and growth of diabetes create a durable pool of patients who may require insulin initiation, intensification and long-duration injection support.
Pen devices reduce the preparation steps associated with vial-and-syringe administration and are designed around repeatable dose selection, replaceable cartridges or ready-to-use prefilled formats. This supports use in homes, workplaces and travel settings and makes training, ergonomics and dose visibility important points of product differentiation.
CMS continues to cap Medicare beneficiary cost sharing at USD 35 for a month’s supply of each covered insulin product. Lower patient cost exposure can support treatment persistence, but it also increases payer scrutiny and heightens competition among insulin brands, biosimilars and delivery formats.
Insulin pens require correct priming, dose selection, needle handling, cartridge compatibility and patient-specific use. The market therefore depends on clear instructions, training and device usability; errors can create clinical risk and make hospitals, clinics, pharmacies and diabetes educators important adoption channels.
Prefilled presentations require coordinated drug manufacturing, cartridge or container supply, device assembly, fill-finish and packaging. Large manufacturers are expanding production networks and packaging capacity, while device specialists compete by offering reusable platforms and standardized 3 mL cartridge compatibility to pharmaceutical partners.
NovoPen 6 and NovoPen Echo Plus automatically record injection time, date and dose units and can transfer injection history to compatible digital applications. The commercial opportunity is not simply connectivity; it is the ability to make multiple daily injection therapy more measurable for patients and clinicians without requiring a pump.
Reusable pens can reduce the amount of device hardware discarded with each cartridge cycle and create longer relationships between manufacturers, insulin brands and users. Ypsomed markets reusable pen platforms compatible with standard 3 mL cartridges, illustrating how pharmaceutical companies can source differentiated device technology without building every pen platform internally.
Awiqli reduces basal insulin injection frequency from daily administration to once weekly. The EU authorization in 2024 and U.S. approval announced in March 2026 broaden the commercial role of pen systems from convenience within daily dosing to a device component of lower-frequency treatment schedules.
The FDA approved Merilog in February 2025 as the first rapid-acting insulin biosimilar, with both a 3 mL prefilled pen and a 10 mL vial presentation. As biosimilar options enter established insulin classes, device usability, contracting, distribution and patient familiarity can become more important competitive variables.
IDF data show 215 million adults with diabetes in the Western Pacific and 107 million in South-East Asia. Conversion from vials to pens will vary by reimbursement, local pricing, cold-chain reliability and diabetes education, but the size of the treated population creates a substantial long-term opportunity for both reusable and disposable formats.
Insulin pen innovation is progressing along three parallel paths: improved mechanical ergonomics, digital dose capture and changes in insulin formulations that alter injection frequency. These developments broaden the basis of competition beyond simple dose delivery.
| Technology Area | Current Commercial Evidence | Market Relevance |
|---|---|---|
| Connected dose memory | NovoPen 6 and NovoPen Echo Plus record dose amount, date and time and can transfer data through NFC to compatible applications. | Supports adherence review, clinician discussion and differentiation of reusable devices. |
| Smart dose support | Commercial smart-pen systems can combine dose logging with application-based dose support and glucose information. | Creates a bridge between conventional multiple daily injections and fully automated pump therapy. |
| Once-weekly basal insulin | Awiqli is administered once weekly; U.S. approval was announced in March 2026 for adults with type 2 diabetes. | Reduces basal injection frequency and increases the strategic importance of pen design for lower-frequency regimens. |
| Reusable cartridge platforms | Reusable devices such as NovoPen and supplier platforms from Ypsomed use replaceable cartridges rather than discarding the entire pen body. | Supports durable-device economics, sustainability objectives and manufacturer platform partnerships. |
The technology opportunity remains constrained by interoperability, regional approvals, training needs and the requirement to preserve dosing safety. Connected features add value when they fit existing clinical workflows and glucose-data ecosystems rather than functioning as isolated device features.
By type, the market is segmented into reusable insulin pens and disposable insulin pens. Both formats remain commercially important because they address different combinations of acquisition cost, convenience, cartridge availability, waste, user familiarity and manufacturer portfolio strategy.
Reusable pens use replaceable insulin cartridges and retain the device body across multiple cartridge cycles. They are well suited to long-term users who value a durable pen, cartridge choice and advanced dose-memory features. Connected reusable platforms can also add digital differentiation without changing the insulin cartridge format.
Disposable prefilled pens combine the insulin container and delivery device in one ready-to-use presentation. They reduce cartridge-loading steps and can simplify initiation, discharge and travel use, but they place greater emphasis on fill-finish capacity, packaging scale and end-of-life waste management.
Reusable pens are positioned to benefit from durable-device and connected-pen innovation, while disposable prefilled pens remain important where simplicity, rapid initiation and standardized dispensing are the primary purchasing considerations.
The market is analyzed across type 1 diabetes management, type 2 diabetes management, gestational diabetes care and other specialized applications. Demand differs by insulin dependence, treatment duration, dosing intensity and the need for patient training.
Type 1 diabetes remains a core insulin-pen application because patients require exogenous insulin and often use multiple daily injections. Pen accuracy, half-unit capability for selected populations, dose memory and portability can influence long-term device preference.
Type 2 diabetes provides the largest incremental population opportunity as disease duration, beta-cell decline and treatment intensification move more patients toward insulin. Once-weekly basal insulin and simplified pen presentations may reduce barriers for patients who are hesitant to begin injectable therapy.
Gestational diabetes can require insulin when lifestyle measures do not achieve glycemic targets. Pen-based dosing can support short-duration treatment and patient self-management, but purchasing volumes are smaller and depend on maternal-care pathways and local clinical practice.
Other uses include insulin management in selected inpatient-to-home transitions and specialized diabetes populations. Commercial demand is driven more by clinical workflow and individualized dosing requirements than by a single uniform patient group.
Type 1 diabetes provides a durable insulin-dependent demand base, while insulin-treated type 2 diabetes is expected to contribute the larger share of incremental patient growth as treatment intensifies globally.
End-user analysis covers hospitals and clinics, homecare settings and ambulatory surgical centers. The balance of market demand is shifting toward self-administration, while clinical facilities remain central to diagnosis, insulin initiation, titration and education.
Hospitals and clinics are important for new insulin starts, complex titration, diabetes education and transitions following acute care. Provider familiarity can strongly influence which pen platform is introduced to a patient and whether the user can operate it safely.
Home use is central to the value proposition of insulin pens because diabetes requires repeated administration outside healthcare facilities. Growth is supported by self-management, dose-memory features, connected applications and the convenience of carrying a compact injection device.
Ambulatory surgical centers represent a smaller use environment, primarily where peri-procedural diabetes management and medication reconciliation create insulin-handling needs. This setting is less central to recurring pen revenue than homecare and routine diabetes clinics.
Homecare is expected to capture a rising share of device use, while hospitals and clinics retain influence over product initiation, training and complex-case management.
Regional demand reflects diabetes prevalence, insulin access, reimbursement, pen penetration, local manufacturing and the maturity of diabetes education. Europe holds the leading market position in 2025, while Asia-Pacific offers the strongest structural growth opportunity.
Europe combines established diabetes care pathways with broad availability of reusable and prefilled pen presentations. The region also remains an early market for lower-frequency insulin innovation: Awiqli received EU-wide marketing authorization in May 2024, supporting continued competition around convenience and treatment burden.
North America is a major insulin-delivery market supported by extensive diabetes treatment infrastructure, strong pharmacy distribution and significant use of prefilled injection formats. U.S. affordability policy and biosimilar approvals are reshaping access and price competition without reducing the importance of device usability.
Medicare beneficiary cost sharing remains capped at USD 35 for a month’s supply of each covered insulin product, while the FDA approved the first rapid-acting insulin biosimilar in a prefilled pen in February 2025.
Source: CMS; U.S. FDA
Asia-Pacific contains the largest global concentration of adults living with diabetes across the Western Pacific and South-East Asia. Growth depends on affordability, diagnosis, insulin initiation, local distribution and the transition from vial-and-syringe therapy to pen formats.
Sanofi markets Toustar as a reusable insulin pen with a dedicated Toujeo cartridge, demonstrating localization of reusable pen delivery for a large and growing diabetes-care market.
Source: Sanofi India
Latin American growth is tied to diabetes diagnosis, public and private insulin coverage, pharmacy access and local availability of branded and biosimilar insulin presentations. Large urban markets can support pen conversion, while affordability and uneven access remain important constraints.
Higher-income Gulf markets support advanced insulin delivery and diabetes services, while many African markets face greater constraints in insulin access, cold-chain infrastructure and patient affordability. Pen adoption therefore varies sharply by country and care setting.
Source: International Diabetes Federation; European Medicines Agency; Sanofi India.
Reimbursement and affordability influence which insulin and pen presentations patients can use consistently. Because the pen is tied to a specific insulin cartridge or prefilled presentation, changes in formulary status and insulin pricing can shift device demand even when the underlying injection preference remains stable.
CMS policy continues the USD 35 monthly cost-sharing cap for each covered insulin product for Medicare beneficiaries. Lower point-of-sale cost exposure can reduce one barrier to insulin persistence and can support broader use of pen presentations where they are included in covered formularies.
The February 2025 FDA approval of Merilog added the first rapid-acting insulin biosimilar in the United States and included a 3 mL prefilled pen. Biosimilar entry can increase price competition in insulin while creating additional choices in ready-to-use pen delivery.
Outside mature reimbursement systems, the effective price difference between vials, cartridges and disposable pens remains a key determinant of adoption. Public tenders, insurance design, retail availability and patient education can therefore influence pen penetration as much as product technology.
Regulatory change is expanding the range of insulin presentations that can be paired with pen delivery, while safety requirements continue to shape device design, labeling and training.
| Regulatory / Product Milestone | Status | Market Relevance |
|---|---|---|
| Awiqli / insulin icodec | EU marketing authorization issued 17 May 2024; U.S. approval announced 27 March 2026 for adults with type 2 diabetes. | Creates a once-weekly basal insulin pen use case and reduces basal injection frequency from seven injections per week to one. |
| Merilog / insulin-aspart-szjj | FDA approved 14 February 2025; first rapid-acting insulin biosimilar in the United States; includes a 3 mL prefilled pen. | Introduces biosimilar competition directly into the prefilled-pen channel. |
| Connected reusable pens | NovoPen 6 and NovoPen Echo Plus record and transfer injection history in markets where approved. | Moves device differentiation toward dose data, interoperability and clinician-facing information. |
Future competitive advantage will depend on matching device features to approved insulin formulations, maintaining dose accuracy and reliability, and achieving region-specific authorization without adding unnecessary complexity for patients.
The insulin pen market combines pharmaceutical manufacturers with device-specialist suppliers. Competition spans insulin portfolio breadth, prefilled-pen manufacturing, reusable device platforms, connected features, human factors, cartridge compatibility and distribution reach.
These companies combine insulin portfolios with established pen presentations and large diabetes commercial organizations. Their advantage is the ability to coordinate drug formulation, device design, manufacturing, training and regional market access.
Independent device specialists compete by supplying reusable and disposable injection platforms that pharmaceutical partners can adapt to their own insulin or peptide portfolios. Engineering flexibility and time-to-market are important purchasing criteria.
BD participates across injection technologies and pen-needle ecosystems, making component quality, safety and compatibility important elements of competitive positioning around the pen itself.
Dose capture, app integration and glucose-data interoperability are creating a higher-value layer above mechanical delivery. The strongest offerings are likely to be those that fit existing treatment workflows and reduce manual dose recording rather than adding complexity.
March 2026: Novo Nordisk announced U.S. FDA approval of Awiqli, the first once-weekly basal insulin for adults with type 2 diabetes, with the company expecting a U.S. launch in the FlexTouch device during the second half of 2026. The approval creates a new low-frequency basal insulin use case for pen delivery.
February 2025: The U.S. FDA approved Merilog (insulin-aspart-szjj), the first rapid-acting insulin biosimilar approved by the agency. The approval includes a 3 mL single-patient-use prefilled pen, increasing competition in a high-frequency insulin-delivery segment.
2025: Novo Nordisk reported continued expansion of its manufacturing network, including new lines and additional fill-finish and packaging capacity in the United States and other major production markets. Greater fill-finish capacity supports supply resilience for a broad injectable portfolio that includes insulin pen presentations.
May 2024: Awiqli received marketing authorization across the European Union. The once-weekly long-acting insulin reduced basal injection frequency relative to daily long-acting insulin, strengthening the commercial link between formulation innovation and pen-device convenience.
Source: Novo Nordisk, March 2026; U.S. FDA, February 2025; Novo Nordisk Annual Report 2025; European Medicines Agency.
The global insulin pen market is projected to expand from USD 6.85 billion in 2026 to USD 28.16 billion by 2034, at a 19.3% CAGR during 2026–2034.
| Forecast Variable | Commercial Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Diabetes treatment base | A large and growing global diabetes population sustains long-duration insulin-delivery demand. | Supports continued patient additions and replacement demand for pen formats. |
| Connected dosing | Dose-memory and data-transfer functions are already commercial in reusable pens. | Raises differentiation beyond mechanics and supports premium device positioning where digital workflows are adopted. |
| Once-weekly insulin | Awiqli introduces a lower-frequency basal injection schedule. | Creates new pen-use patterns and can reduce the perceived burden of basal insulin initiation and persistence. |
| Biosimilar access | Rapid-acting biosimilar insulin is now approved in a prefilled-pen presentation in the United States. | Can broaden product choice and shift competition toward price, availability and device usability. |
| Regional mix | Europe remains the leading 2025 market, while Asia-Pacific contains the largest diabetes population pool. | Future value creation increasingly depends on affordability and pen conversion in emerging and high-volume markets. |
The study is structured to support insulin-delivery strategy, device-platform planning, portfolio assessment, regional opportunity analysis and competitive benchmarking across the global insulin pen market.
Market sizing combines bottom-up assessment of insulin pen manufacturers, product portfolios, pen presentations, distribution presence and regional adoption with top-down analysis of insulin-treated patient populations, pen penetration, device replacement patterns and treatment access. The 2025 base, 2026 estimate and 2034 forecast are developed within one consistent global revenue framework.
Primary research is used to validate device adoption, procurement priorities, channel behavior, patient training requirements and competitive positioning. Secondary research prioritizes regulators, diabetes epidemiology authorities, official reimbursement sources, company filings and product documentation. External market-research publishers are not used as evidence.
Forecasts incorporate diabetes prevalence, insulin initiation, vial-to-pen conversion, reusable-versus-disposable mix, connected-device adoption, once-weekly insulin uptake, biosimilar competition, reimbursement changes, manufacturing capacity and regional access. Segment conclusions are kept qualitative when a defensible public share or CAGR is not available.
The global insulin pen market was valued at USD 5.74 billion in 2025 and is estimated at USD 6.85 billion in 2026. It is projected to reach USD 28.16 billion by 2034, representing a 19.3% CAGR during 2026–2034.
The report covers reusable insulin pens that accept replaceable cartridges and disposable prefilled insulin pens.
The report analyzes type 1 diabetes management, type 2 diabetes management, gestational diabetes care and other specialized applications.
Hospitals and clinics, homecare settings and ambulatory surgical centers are included in the end-user analysis.
Europe holds the leading market position in 2025, while Asia-Pacific presents the strongest structural growth opportunity as diabetes treatment and pen adoption expand.
Growth is supported by the expanding diabetes population, self-administration, conversion from vials to pens, connected dose tracking, improved access to insulin and new lower-frequency treatment options.
Connected pens can automatically record dose amount and timing and transfer injection histories to compatible applications, adding data visibility and adherence support to reusable pen platforms.
The report profiles Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, Ypsomed Holding AG, Owen Mumford Ltd. and Becton, Dickinson and Company.
Government, Regulators & Public Bodies
Epidemiology & Clinical Authorities
Company Primary Sources
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
